Whether free fatty acid (FFA) rate of appearance (R a ) is increased in type 2 diabetes is controversial. To characterize nocturnal and postprandial abnormalities in FFA kinetics and to determine the effects of treatment with insulin sensitizers on lipolysis, we measured palmitate R a in control subjects (n ؍ 6) and individuals with poorly controlled, sulfonylurea-treated type 2 diabetes (HbA 1c ؍ 8.7 ؎ 0.2%, n ؍ 20), the latter before and at the end of 12 weeks of treatment with troglitazone (600 mg/day, n ؍ 4), metformin (ϳ2,000 mg/day, n ؍ 8), or placebo (n ؍ 8). Subjects consumed a standard breakfast at 0800 h. Results in control subjects and type 2 diabetic subjects were compared at baseline. Integrated nocturnal FFA R a (AUC 1:00 -8:00 A.M. ) was ϳ50% higher in type 2 diabetic subjects than in control subjects (29.4 ؎ 3.0 vs. 19.4 ؎ 3.9 mmol ⅐ m ؊2 ⅐ 7 h ؊1 , respectively, P < 0.05), whereas postprandial palmitate R a (AUC 0 -240 min ) was almost threefold higher in type 2 diabetic subjects than in control subjects (14.2 ؎ 1.7 vs. 5.3 ؎ 1.0 mmol ⅐ m ؊2 ⅐ 4 h ؊1 , respectively, P < 0.01). After troglitazone treatment, nocturnal palmitate R a did not change, but postprandial palmitate R a decreased by ϳ30% (P < 0.05). Palmitate kinetics did not change with metformin or placebo treatment. In summary, nocturnal and postprandial FFA R a is increased in type 2 diabetes. Postprandial lipolysis appears to be preferentially improved by thiazolidinediones compared with nocturnal lipolysis. Diabetes 52:675-681, 2003 P atients with type 2 diabetes have resistance to the antilipolytic effects of insulin on adipose tissue (1,2). This dysregulation of adipose tissue lipolysis has been implicated as a major cause of the abnormalities in lipoprotein and glucose metabolism that are characteristic of type 2 diabetes (3). However, plasma free fatty acid (FFA) turnover has been reported to be both increased (4) and normal (5-8) in type 2 diabetes.FFA tracer studies in patients with type 2 diabetes have generally been performed under postabsorptive conditions (4,5,7) or during a hyperinsulinemic-euglycemic clamp (1,2); little information is available regarding nocturnal and postprandial FFA metabolism. In fact, patients with poorly controlled type 2 diabetes exhibit an increase in plasma FFA concentrations during the night (9), but it is not known whether this is the result of increased release of FFA into the systemic circulation or decreased plasma FFA clearance. An understanding of fatty acid metabolism during nocturnal and absorptive conditions is important because postabsorptive measurements may not necessarily reflect conditions at other times of the day.The treatment of type 2 diabetes has been revolutionized by the availability of medications, including biguanides and thiazolidinediones, which improve insulin action on glucose metabolism. In addition, some (10,11) but not all (12) studies suggest that these agents may improve abnormalities in FFA metabolism in the postabsorptive state and during hyperinsulin...